Legend Biotech Statistics
Want to see LEGN full AI Analyst Report?
Legend Biotech (LEGN) Stock Statistics & Valuation Metrics
Total Valuation
Legend Biotech has a market cap or net worth of $3.39B. The enterprise value is $3.30B.
- Market Cap
- $3.39B
- Enterprise Value
- $3.30B
Share Statistics
Legend Biotech has 194,488,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 194,488,420
- Owned by Insiders
- 0.93%
- Owned by Institutions
- 26.72%
Financial Efficiency
Legend Biotech’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -9.59%.
- Return on Equity (ROE)
- -0.30
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -9.59%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 311.79K
- Profits Per Employee
- -89.94K
- Employee Count
- 3,300
- Asset Turnover
- 0.59
- Inventory Turnover
- 12.75
Valuation Ratios
The current PE Ratio of Legend Biotech is -1750.00. Legend Biotech’s PEG ratio is -9.41.
- PE Ratio
- -1750.00
- PS Ratio
- 2.38
- PB Ratio
- 2.57
- Price to FCF
- -10.09
- Price to Operating Cash Flow
- -13.21
- PEG Ratio
- -9.41
Income Statement
In the last 12 months, Legend Biotech had revenue of 1.03B and earned -296.80M in profits. Earnings per share was -1.60.
- Revenue
- 1.03B
- Gross Profit
- 620.80M
- Operating Income
- -136.50M
- Pretax Income
- -282.60M
- Net Income
- -296.80M
- EBITDA
- -232.30M
- Earnings Per Share (EPS)
- -1.60
Cash Flow
In the last 12 months, operating cash flow was -247.80M and capital expenditures -73.11M, giving a free cash flow of -320.88M billion.
- Operating Cash Flow
- -247.80M
- Free Cash Flow
- -320.88M
- Free Cash Flow per Share
- -1.72
Dividends & Yields
Legend Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.91%
- Earnings Yield
- >-0.01%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- -43.57%
- 50-Day Moving Average
- 19.65
- 200-Day Moving Average
- 22.29
- Relative Strength Index (RSI)
- 37.53
- Average Volume (3m)
- 2.23M
Important Dates
Legend Biotech upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Legend Biotech as a current ratio of 1.96, with Debt / Equity ratio of 41.28%
- Current Ratio
- 1.96
- Quick Ratio
- 1.91
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- 2.10
- Interest Coverage Ratio
- -6.38
Taxes
In the past 12 months, Legend Biotech has paid 14.20M in taxes.
- Income Tax
- 14.20M
- Effective Tax Rate
- -0.05
Enterprise Valuation
Legend Biotech EV to EBITDA ratio is 29.57, with an EV/FCF ratio of -9.17.
- EV to Sales
- 2.17
- EV to EBITDA
- 29.57
- EV to Free Cash Flow
- -9.17
- EV to Operating Cash Flow
- -11.88
Balance Sheet
Legend Biotech has $852.50M in cash and marketable securities with $167.40M in debt, giving a net cash position of $685.10M billion.
- Cash & Marketable Securities
- $852.50M
- Total Debt
- $167.40M
- Net Cash
- $685.10M
- Net Cash Per Share
- $3.52
- Tangible Book Value Per Share
- $6.42
Margins
Gross margin is 56.98%, with operating margin of 2.51%, and net profit margin of -0.02%.
- Gross Margin
- 56.98%
- Operating Margin
- 2.51%
- Pretax Margin
- 2.37%
- Net Profit Margin
- -0.02%
- EBITDA Margin
- 7.33%
- EBIT Margin
- 3.63%
Analyst Forecast
The average price target for Legend Biotech is $41.90, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $41.90
- Price Target Upside
- 139.43% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- 49.73%
- EPS Growth Forecast
- 98.75%
Scores
- Smart Score
- 6
- AI Score
- 52
